Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 1.2 %

Shares of EVOK stock opened at $4.90 on Friday. The stock has a 50-day simple moving average of $4.95 and a 200 day simple moving average of $5.28. The stock has a market capitalization of $7.28 million, a P/E ratio of -0.45 and a beta of 0.16. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $14.04.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.